Inger L. Rosner

1.7k total citations
67 papers, 1.1k citations indexed

About

Inger L. Rosner is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Molecular Biology. According to data from OpenAlex, Inger L. Rosner has authored 67 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Pulmonary and Respiratory Medicine, 16 papers in Cancer Research and 14 papers in Molecular Biology. Recurrent topics in Inger L. Rosner's work include Prostate Cancer Treatment and Research (42 papers), Prostate Cancer Diagnosis and Treatment (30 papers) and Cancer, Lipids, and Metabolism (11 papers). Inger L. Rosner is often cited by papers focused on Prostate Cancer Treatment and Research (42 papers), Prostate Cancer Diagnosis and Treatment (30 papers) and Cancer, Lipids, and Metabolism (11 papers). Inger L. Rosner collaborates with scholars based in United States, Denmark and Pakistan. Inger L. Rosner's co-authors include David G. McLeod, Jennifer Cullen, Shiv Srivastava, Yongmei Chen, Isabell A. Sesterhenn, Timothy C. Brand, Jennifer Cullen, Amina Ali, Lauren M. Hurwitz and Tara Maddala and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Cancer.

In The Last Decade

Inger L. Rosner

65 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Inger L. Rosner United States 20 730 277 259 196 124 67 1.1k
Karol Axcrona Norway 22 654 0.9× 248 0.9× 299 1.2× 245 1.3× 140 1.1× 63 1.2k
Sven Wenske United States 21 684 0.9× 188 0.7× 190 0.7× 172 0.9× 283 2.3× 41 1.2k
Julia H. Hayes United States 11 501 0.7× 155 0.6× 96 0.4× 183 0.9× 107 0.9× 22 776
Lawrence R. Ragard United States 13 360 0.5× 168 0.6× 136 0.5× 253 1.3× 194 1.6× 28 1.1k
Joep G.H. van Roermund Netherlands 20 573 0.8× 149 0.5× 154 0.6× 182 0.9× 162 1.3× 41 914
Jan-Erik Johansson Sweden 8 726 1.0× 107 0.4× 121 0.5× 210 1.1× 225 1.8× 9 951
J.F. Lester United Kingdom 20 1.0k 1.4× 192 0.7× 150 0.6× 638 3.3× 158 1.3× 84 1.5k
Michael Aitchison United Kingdom 19 444 0.6× 395 1.4× 176 0.7× 233 1.2× 293 2.4× 45 866
Thomas L. Riley United States 15 815 1.1× 160 0.6× 143 0.6× 492 2.5× 199 1.6× 27 1.5k

Countries citing papers authored by Inger L. Rosner

Since Specialization
Citations

This map shows the geographic impact of Inger L. Rosner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Inger L. Rosner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Inger L. Rosner more than expected).

Fields of papers citing papers by Inger L. Rosner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Inger L. Rosner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Inger L. Rosner. The network helps show where Inger L. Rosner may publish in the future.

Co-authorship network of co-authors of Inger L. Rosner

This figure shows the co-authorship network connecting the top 25 collaborators of Inger L. Rosner. A scholar is included among the top collaborators of Inger L. Rosner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Inger L. Rosner. Inger L. Rosner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Young, Denise, Jesse Fox, Jiji Jiang, et al.. (2022). Focal p53 protein expression and lymphovascular invasion in primary prostate tumors predict metastatic progression. Scientific Reports. 12(1). 5404–5404. 15 indexed citations
2.
3.
Cullen, Jennifer, Samantha A. Streicher, Huai‐Ching Kuo, et al.. (2020). Race, tumor location, and disease progression among low‐risk prostate cancer patients. Cancer Medicine. 9(6). 2235–2242. 10 indexed citations
4.
Hurwitz, Lauren M., Huai‐Ching Kuo, Timothy C. Brand, et al.. (2020). A prospective analysis of health-related quality of life in intermediate and high-risk prostate cancer patients managed with intensity modulated radiation therapy, with vs. without hormonal therapy. Urologic Oncology Seminars and Original Investigations. 38(10). 794.e1–794.e9. 4 indexed citations
5.
Tan, Shyh‐Han, Denise Young, Yongmei Chen, et al.. (2020). Prognostic features of Annexin A2 expression in prostate cancer. Pathology. 53(2). 205–213. 20 indexed citations
6.
Markowski, Mark C., Yongmei Chen, Zhaoyong Feng, et al.. (2019). PSA Doubling Time and Absolute PSA Predict Metastasis-free Survival in Men With Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. Clinical Genitourinary Cancer. 17(6). 470–475.e1. 33 indexed citations
7.
Mohamed, Ahmed A., Charles P. Xavier, Gauthaman Sukumar, et al.. (2018). Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell Growth. Cancer Research. 78(13). 3659–3671. 44 indexed citations
8.
Salter, Carolyn A., Jennifer Cullen, Huai‐Ching Kuo, et al.. (2018). Alkaline Phosphatase Kinetics Predict Metastasis among Prostate Cancer Patients Who Experience Relapse following Radical Prostatectomy. BioMed Research International. 2018. 1–7. 3 indexed citations
9.
Hurwitz, Lauren M., Jennifer Cullen, Erika M. Wolff, et al.. (2017). A prospective study of health-related quality-of-life outcomes for patients with low-risk prostate cancer managed by active surveillance or radiation therapy. Urologic Oncology Seminars and Original Investigations. 35(5). 234–242. 14 indexed citations
10.
Hawksworth, Dorota J., Lauren M. Hurwitz, Jennifer Cullen, et al.. (2015). A prospective, randomized, placebo‐controlled trial of on‐Demand vs. nightly sildenafil citrate as assessed by Rigiscan and the international index of erectile function. Andrology. 4(1). 27–32. 18 indexed citations
11.
Hurwitz, Lauren M., Jennifer Cullen, Sally Elsamanoudi, et al.. (2015). A prospective cohort study of treatment decision-making for prostate cancer following participation in a multidisciplinary clinic. Urologic Oncology Seminars and Original Investigations. 34(5). 233.e17–233.e25. 34 indexed citations
12.
13.
Young, Denise, Yongmei Chen, Jennifer Cullen, et al.. (2014). Predominance of ERG-negative high-grade prostate cancers in African American men. Molecular and Clinical Oncology. 2(6). 982–986. 20 indexed citations
14.
Sesterhenn, Isabell A., Inger L. Rosner, Jennifer Cullen, et al.. (2013). Anterior tumors of the prostate: clinicopathological features and outcomes. Prostate Cancer and Prostatic Diseases. 17(1). 75–80. 36 indexed citations
15.
Snir, Ayelet, Aharon Kessel, Tharwat Haj, et al.. (2011). Anti-IL-6 receptor antibody (tocilizumab): a B cell targeting therapy.. PubMed. 29(4). 697–700. 41 indexed citations
16.
Sterbis, Joseph R., Chunling Gao, Bungo Furusato, et al.. (2008). Higher Expression of the Androgen-Regulated Gene PSA/HK3 mRNA in Prostate Cancer Tissues Predicts Biochemical Recurrence-Free Survival. Clinical Cancer Research. 14(3). 758–763. 18 indexed citations
17.
Furusato, Bungo, Inger L. Rosner, David J. Osborn, et al.. (2008). Do patients with low volume prostate cancer have prostate specific antigen recurrence following radical prostatectomy?. Journal of Clinical Pathology. 61(9). 1038–1040. 7 indexed citations
18.
Rosner, Inger L., Lakshmi Ravindranath, Bungo Furusato, et al.. (2007). Higher Tumor to Benign Ratio of the Androgen Receptor mRNA Expression Associates with Prostate Cancer Progression after Radical Prostatectomy. Urology. 70(6). 1225–1229. 25 indexed citations
19.
Brassell, Stephen A., Inger L. Rosner, & David G. McLeod. (2005). Update on magnetic resonance imaging, ProstaScint, and novel imaging in prostate cancer*. Current Opinion in Urology. 15(3). 163–166. 27 indexed citations
20.
Rosner, Inger L., et al.. (1972). Effets protecteurs du pentanicotinate de xylitol dans l'hypoxie et l'anoxie asphyxique.. Therapies. 27(6). 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Karol Axcrona Breakdown of academic impact, for papers by Sven Wenske Breakdown of academic impact, for papers by Julia H. Hayes Breakdown of academic impact, for papers by Lawrence R. Ragard Breakdown of academic impact, for papers by Joep G.H. van Roermund Breakdown of academic impact, for papers by Jan-Erik Johansson Breakdown of academic impact, for papers by J.F. Lester Breakdown of academic impact, for papers by Michael Aitchison Breakdown of academic impact, for papers by Thomas L. Riley
Rankless by CCL
2026